AI Pressure Hits Research Segment

MPS Ltd's latest quarterly results show a company in transition. While Q3 FY2026 revenue and profit declined year-on-year, management described it as a 'holding quarter.' The company views these figures as part of a strategic repositioning, not a business slowdown. MPS faces the challenge of executing this pivot and demonstrating clear progress, especially as AI and other technological advancements reshape the information services market.

MPS Ltd's Q3 FY2026 revenue fell 2.1% to Rs 182.5 crore and net profit dropped 12.8% to Rs 35.5 crore, though operating margins held steady at 31.6%. This slowdown is mainly in the American Journal Experts (AJE) business, part of the Research Solutions segment. AJE, which serves individual researchers, is facing pressure from AI tools, impacting parts of the academic and professional information market. Excluding AJE, the core Research Solutions business grew 6.5% in the quarter, and the Education Solutions segment grew 11.3%. The Corporate Learning segment is undergoing a 'deliberate reset,' with revenue down over 24% as the company moves from low-margin legacy projects to higher-value, AI-driven services. Despite these mixed results, MPS Ltd has a strong balance sheet with minimal debt and Rs 143 crore in cash reserves as of December 2025. The stock traded around ₹1,657.70 on May 2, 2026, with a trailing P/E of roughly 16.35, a discount to its 5-year median of 20. The valuation reflects market uncertainty about the company's transition.

Unbound Medicine Acquisition Fuels Platform Strategy

The strategic acquisition of Unbound Medicine in January 2026 for $16.5 million is a key step toward MPS's platform-led, recurring-revenue model. Unbound Medicine, a U.S.-based healthcare technology firm, offers AI clinical decision support and medical reference tools for institutions. This targets the fast-growing healthcare IT services sector, projected to hit USD 96.4 billion in 2026 and expand further. Unbound has a 14% EBITDA margin; MPS aims to raise this to 30% by FY2027 via synergies. This acquisition diversifies MPS's revenue beyond project work, introducing a subscription model that complements its digital content and platform engineering. In the wider EdTech market, AI integration is rapid, with 92% of university students using AI tools, boosting demand for advanced educational technology. Competitors like RELX (P/E ~23.7-24.1) and Pearson (P/E ~21.2-21.5) trade at higher multiples. This suggests MPS's current valuation may not fully capture its quality, but rather the market's need for clearer earnings visibility. Wolters Kluwer, a healthcare information leader, is also integrating AI into its UpToDate platform, focusing on 'Expert AI' from verified content to ensure trust and reduce risks.

Challenges and Execution Risks Remain

While MPS Ltd has a strong balance sheet and high return ratios (ROE >30%, ROCE >40%), the company faces execution risks during its strategic transition. Reliance on the AJE segment for revenue, which is directly exposed to AI disruption, remains a challenge. Additionally, the 'reset' in Corporate Learning, aimed at long-term quality, currently depresses financial performance. Market perception of predictability is key. The shift to platform models and new areas like healthcare knowledge systems, while structurally better, makes modeling future earnings more complex. The Unbound acquisition, while strategically sound, involves integration risks and needs successful synergy realization to justify its price and boost margins. Competitors RELX and Pearson trade at higher P/E multiples, suggesting the market values greater visibility or more established platforms. MPS is still building its 'multi-engine' growth model. Limited institutional ownership, with promoters holding ~68%, means valuation gains will depend on sustained delivery and clearer future visibility, rather than broad institutional buying. Management's track record shows no immediate red flags. However, past acquisitions like distressed AJE, which had much lower EBITDA margins than average, point to potential integration complexities.

Management Sees Growth Ahead

Management expects FY2026 earnings per share to exceed Rs 100. An inflection point is projected for FY2027, with stabilization expected in Research Solutions as AJE's impact lessens. Education Solutions is expected to continue its double-digit growth, backed by long-term contracts. Corporate Learning is forecast to recover after restructuring, targeting higher-margin services. Unbound Medicine is expected to contribute significantly through its subscription base and cross-selling. This move to a multi-engine growth model offers greater opportunity but requires strong execution and clear communication to turn strategic shifts into market value.